or Try an Advanced Search...

    Technical Analysis for NGEN - Nervgen Pharma Corp

    Grade Last Price % Change Price Change
    F 2.290 2.23% 0.050
    NGEN closed down 1.75 percent on Wednesday, November 20, 2024, on 29 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical NGEN trend table...
    Date Alert Name Type % Chg
    180 Bearish Setup Bearish Swing Setup 2.23%
    Calm After Storm Range Contraction 2.23%
    NR7 Range Contraction 2.23%
    NR7-2 Range Contraction 2.23%
    Wide Bands Range Expansion 2.23%
    Oversold Stochastic Weakness 2.23%
    Calm After Storm Range Contraction 0.44%
    NR7 Range Contraction 0.44%
    Inside Day Range Contraction 0.44%
    Wide Bands Range Expansion 0.44%
    Older End-of-Day Signals for NGEN ...

       Recent Intraday Alerts

    Alert Time
    Up 2% 25 minutes ago
    Up 1% 25 minutes ago
    Down 2% about 19 hours ago
    Down 1% about 20 hours ago
    Possible NR7 about 20 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    NGEN Chart by TradingView
    Basic chart:

    Profile

    NervGen Pharma Corp. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of nerve damage. Its product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University of Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is headquartered in Vancouver, Canada.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Health Pharma Pharmaceutical Clinic Pharmaceutical Products

    Is NGEN a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 14 NervGen Pharma Reports Q3 2024 Financial Results and Operational Updates
    Nov 7 NervGen Pharma to Present at the Stifel 2024 Healthcare Conference
    Aug 27 NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    Aug 18 Here's Why We're Not At All Concerned With NervGen Pharma's (CVE:NGEN) Cash Burn Situation
    Aug 6 NervGen Pharma to Present at the Canaccord Genuity 44th Annual Growth Conference
    Jun 25 NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage
    Jun 20 NervGen Pharma to Present at the 2nd Annual Spinal Cord Injury Investor Symposium
    Jun 6 NervGen Pharma Grants Stock Options
    Jun 5 NervGen Pharma Announces Results of Annual General Meeting of Shareholders
    See more NGEN news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.98
    52 Week Low 1.58
    Average Volume 43,900
    200-Day Moving Average 2.574
    50-Day Moving Average 2.478
    20-Day Moving Average 2.463
    10-Day Moving Average 2.434
    Average True Range 0.158
    RSI (14) 42.53
    ADX 18.86
    +DI 26.806
    -DI 29.146
    Chandelier Exit (Long, 3 ATRs) 2.325
    Chandelier Exit (Short, 3 ATRs) 2.525
    Upper Bollinger Bands 2.835
    Lower Bollinger Band 2.090
    Percent B (%b) 0.2
    BandWidth 30.221
    MACD Line -0.056
    MACD Signal Line -0.021
    MACD Histogram -0.0352
    Fundamentals Value
    Market Cap 78.66 Million
    Num Shares 35.1 Million
    EPS -0.30
    Price-to-Earnings (P/E) Ratio -7.44
    Price-to-Sales 0.00
    Price-to-Book 6.30
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.360
    Resistance 3 (R3) 2.367 2.333 2.340
    Resistance 2 (R2) 2.333 2.303 2.330 2.333
    Resistance 1 (R1) 2.287 2.284 2.270 2.280 2.327
    Pivot Point 2.253 2.253 2.245 2.250 2.253
    Support 1 (S1) 2.207 2.223 2.190 2.200 2.153
    Support 2 (S2) 2.173 2.204 2.170 2.147
    Support 3 (S3) 2.127 2.173 2.140
    Support 4 (S4) 2.120